How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Outbreaks News Archives

Login / Signup

Early Release – Integrating Prevention and Response at the Crossroads of Henipavirus Preparedness, Hendra@30 Conference, 2024 – Volume 32, Number 1—January 2026 – Emerging Infectious Diseases journal

Early Release – Nocardia and the Death of Raphael (1520) – Volume 32, Number 1—January 2026 – Emerging Infectious Diseases journal

Early Release – Molecular Analysis of Emerging MT27 Macrolide-Resistant Bordetella pertussis, Kobe, Japan, 2025 – Volume 32, Number 1—January 2026 – Emerging Infectious Diseases journal

Early Release – Serologic Evidence of Exposure to Burkholderia pseudomallei, Nigeria – Volume 32, Number 1—January 2026 – Emerging Infectious Diseases journal

Early Release – Mycobacterium decipiens Infection in Patient Receiving Anti–TNF-α Therapy, France, 2024 – Volume 32, Number 1—January 2026 – Emerging Infectious Diseases journal

Early Release – Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018 – Volume 32, Number 1—January 2026 – Emerging Infectious Diseases journal

Early Release – Predictors of Fatal Outcomes among Pediatric Patients Hospitalized for Rocky Mountain Spotted Fever, Sonora, Mexico, 2004–2024 – Volume 32, Number 2—February 2026 – Emerging Infectious Diseases journal

Early Release – Detection of Oropouche and Punta Toro Virus Infections by Enhanced Surveillance, Panama, 2023–2024 – Volume 32, Number 1—January 2026 – Emerging Infectious Diseases journal

Early Release – Disseminated Nocardia ignorata Infection with Splenic and Brain Involvement in Patient with Large B-Cell Lymphoma – Volume 32, Number 1—January 2026 – Emerging Infectious Diseases journal

Early Release – Emergence of New Delhi Metallo-β-Lactamase 14–Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands – Volume 32, Number 1—January 2026 – Emerging Infectious Diseases journal

Schedule an Appointment

Quick Links

Patient Forms

Contact Us